2024 Q1 Form 10-K Financial Statement

#000149315224011616 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.415M $9.743M
YoY Change -40.37% -28.83%
% of Gross Profit
Research & Development $3.294M $3.553M $11.29M
YoY Change 25.73% 18.43% -3.8%
% of Gross Profit
Depreciation & Amortization $70.30K $71.64K $248.2K
YoY Change -63.51% -67.44% -66.08%
% of Gross Profit
Operating Expenses $5.011M $5.968M $21.03M
YoY Change -11.84% -15.35% -17.27%
Operating Profit -$5.011M -$21.03M
YoY Change -11.84% -15.61%
Interest Expense $195.4K $197.1K
YoY Change 95.43% -96.08%
% of Operating Profit
Other Income/Expense, Net $81.92K -$396.3K $235.1K
YoY Change -11.99% -107.34% -101.87%
Pretax Income -$6.169M -$20.80M
YoY Change -58.32% -44.49%
Income Tax -$1.280M -$1.280M
% Of Pretax Income
Net Earnings -$4.900M -$4.888M -$19.50M
YoY Change -12.36% -63.05% -45.68%
Net Earnings / Revenue
Basic Earnings Per Share -$0.52 -$2.16
Diluted Earnings Per Share -$0.52 -$0.52 -$2.16
COMMON SHARES
Basic Shares Outstanding 9.400M shares 9.399M shares 9.045M shares
Diluted Shares Outstanding 9.400M shares 9.045M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.809M $15.70M $15.70M
YoY Change -68.54% -52.07% -54.17%
Cash & Equivalents $2.347M $5.839M $5.839M
Short-Term Investments $7.462M $9.857M $9.857M
Other Short-Term Assets $2.285M $2.545M $2.545M
YoY Change -18.08% -8.45% -8.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.09M $18.24M $18.24M
YoY Change -66.71% -50.91% -50.9%
LONG-TERM ASSETS
Property, Plant & Equipment $693.4K $751.9K $2.347M
YoY Change 24.72% 37.13% 235.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $1.537M $2.925M $1.330M
YoY Change -70.54% -53.36% -17.88%
Total Long-Term Assets $2.230M $3.677M $3.677M
YoY Change -61.37% -46.09% -46.16%
TOTAL ASSETS
Total Short-Term Assets $12.09M $18.24M $18.24M
Total Long-Term Assets $2.230M $3.677M $3.677M
Total Assets $14.32M $21.92M $21.92M
YoY Change -65.98% -50.16% -50.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.358M $3.515M $3.515M
YoY Change -40.66% -1.99% -2.08%
Accrued Expenses $1.959M $3.391M $3.876M
YoY Change -49.96% -29.29% -22.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $4.817M $7.391M $7.391M
YoY Change -53.76% -26.36% -26.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $1.008M $1.139M $1.139M
YoY Change -11.57%
Total Long-Term Liabilities $1.008M $1.139M $1.139M
YoY Change -80.0% -75.29% -75.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.817M $7.391M $7.391M
Total Long-Term Liabilities $1.008M $1.139M $1.139M
Total Liabilities $5.825M $8.530M $8.530M
YoY Change -62.32% -41.76% -41.77%
SHAREHOLDERS EQUITY
Retained Earnings -$393.1M -$388.0M
YoY Change 5.04% 5.15%
Common Stock $94.01K $94.00K
YoY Change 3.34% 26.41%
Preferred Stock
YoY Change
Treasury Stock (at cost) $85.19K $85.19K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $8.500M $13.39M $13.39M
YoY Change
Total Liabilities & Shareholders Equity $14.32M $21.92M $21.92M
YoY Change -65.98% -50.16% -50.16%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.900M -$4.888M -$19.50M
YoY Change -12.36% -63.05% -45.68%
Depreciation, Depletion And Amortization $70.30K $71.64K $248.2K
YoY Change -63.51% -67.44% -66.08%
Cash From Operating Activities -$5.900M -$3.772M -$19.00M
YoY Change 44.41% -25.45% -17.86%
INVESTING ACTIVITIES
Capital Expenditures $11.76K $0.00 $451.8K
YoY Change -79.43% -100.0% 68.69%
Acquisitions
YoY Change
Other Investing Activities $2.394M -$3.304M $11.46M
YoY Change 312.77% -69.38% 33.55%
Cash From Investing Activities $2.382M -$3.304M $11.01M
YoY Change 358.76% -69.5% 32.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.781M
YoY Change -58.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.25K -$3.639M
YoY Change -93.12% -154.12%
NET CHANGE
Cash From Operating Activities -$5.900M -3.772M -$19.00M
Cash From Investing Activities $2.382M -3.304M $11.01M
Cash From Financing Activities 30.25K -$3.639M
Net Change In Cash -$3.492M -7.046M -$11.65M
YoY Change 219.73% -54.4% 44.0%
FREE CASH FLOW
Cash From Operating Activities -$5.900M -$3.772M -$19.00M
Capital Expenditures $11.76K $0.00 $451.8K
Free Cash Flow -$5.912M -$3.772M -$19.45M
YoY Change 42.7% -26.18% -16.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Debt Securities Held To Maturity Accrued Interest After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLoss
usd
CY2023Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
usd
CY2023Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023 IMNN Gain Loss From Change In Earnout Milestone Liability
GainLossFromChangeInEarnoutMilestoneLiability
usd
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
usd
CY2023 IMNN Gain Loss From Change In Earnout Milestone Liability
GainLossFromChangeInEarnoutMilestoneLiability
usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
usd
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
usd
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
CY2023 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
usd
CY2023 us-gaap Payments For Repurchase Of Redeemable Convertible Preferred Stock
PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
usd
CY2022 IMNN Paymentoff Of Loan And Accrued Endofterm Fees
PaymentoffOfLoanAndAccruedEndoftermFees
usd
CY2022 IMNN Recognition Of Right Use Asset And Liability
RecognitionOfRightUseAssetAndLiability
usd
CY2022 IMNN Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
usd
CY2023Q4 IMNN Available For Sale Securities Unrealized Loss Fair Value
AvailableForSaleSecuritiesUnrealizedLossFairValue
usd
CY2023Q4 IMNN Available For Sale Securities Unrealized Holding Losses Less Than Twelve Months
AvailableForSaleSecuritiesUnrealizedHoldingLossesLessThanTwelveMonths
usd
CY2023Q4 us-gaap Restricted Investments
RestrictedInvestments
usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
usd
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2022 IMNN Effective Income Tax Rate Reconciliation Time Up
EffectiveIncomeTaxRateReconciliationTimeUp
pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
pure
CY2022Q4 IMNN Deferred Tax Assets Legal Act
DeferredTaxAssetsLegalAct
usd
CY2022Q4 IMNN Earnout Milestone Liability
EarnoutMilestoneLiability
usd
CY2023Q4 IMNN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-15911
CY2023 dei Entity Registrant Name
EntityRegistrantName
IMUNON, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-1256615
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
997 LENOX DRIVE
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 100
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
LAWRENCEVILLE
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08648
CY2023 dei City Area Code
CityAreaCode
(609)
CY2023 dei Local Phone Number
LocalPhoneNumber
896-9100
CY2023 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.01 Per Share
CY2023 dei Trading Symbol
TradingSymbol
IMNN
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
11900000 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9399789 shares
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5838566 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11492841 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9857087 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
21254485 usd
CY2022Q4 us-gaap Debt Securities Held To Maturity Accrued Interest After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLoss
128932 usd
CY2022Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
1500000 usd
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
2545051 usd
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
2403433 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
18240704 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
36779691 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
751906 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
548301 usd
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
4500000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1280385 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1567026 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1595074 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
155876 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
50000 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
425000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2925459 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6647902 usd
CY2023Q4 us-gaap Assets
Assets
21918069 usd
CY2022Q4 us-gaap Assets
Assets
43975894 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3515192 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3586623 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3390521 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4794936 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1424774 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
485421 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
230749 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7391134 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10037082 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
4610946 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1139293 usd
CY2023Q4 us-gaap Liabilities
Liabilities
8530427 usd
CY2022Q4 us-gaap Liabilities
Liabilities
14648028 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
112500000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
112500000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9399811 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7436219 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9399789 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7436197 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
93998 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
74362 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
401500838 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
397980023 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
60796 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26494 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388182802 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-368667825 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35863766 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19514977 usd
CY2023Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
13472830 usd
CY2022Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
29413054 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
22 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
22 shares
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
85188 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
85188 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13387642 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29327866 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21918069 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43975894 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
500000 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11287691 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11733666 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9742739 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13687899 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
21030430 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
25421565 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-21030430 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-24921565 usd
CY2022 IMNN Gain Loss From Change In Earnout Milestone Liability
GainLossFromChangeInEarnoutMilestoneLiability
5396000 usd
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
13366234 usd
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-329158 usd
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
1157625 usd
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
453356 usd
CY2023 us-gaap Interest Expense
InterestExpense
197080 usd
CY2022 us-gaap Interest Expense
InterestExpense
5028618 usd
CY2023 us-gaap Other Income
OtherIncome
-396319 usd
CY2022 us-gaap Other Income
OtherIncome
1801 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
235068 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12543695 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20795362 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37465260 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1280385 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1567026 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19514977 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35898234 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.03
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9045320 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9045320 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7142970 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7142970 shares
CY2023 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-431801 usd
CY2022 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-49222 usd
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-397499 usd
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14754 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19480675 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35898234 usd
CY2023 us-gaap Depreciation
Depreciation
248154 usd
CY2022 us-gaap Depreciation
Depreciation
196510 usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
471851 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
535119 usd
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
500000 usd
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-34302 usd
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-34468 usd
CY2022 IMNN Gain Loss From Change In Earnout Milestone Liability
GainLossFromChangeInEarnoutMilestoneLiability
5396000 usd
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-329158 usd
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
375000 usd
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
13366234 usd
CY2023 IMNN Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable
AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable
55122 usd
CY2022 IMNN Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable
AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable
181259 usd
CY2023 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-68136 usd
CY2022 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
20088 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
141619 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-43980 usd
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
241511 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1992929 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2111901 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19022148 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23096895 usd
CY2023 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
13541806 usd
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
48226390 usd
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
25000000 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
56775000 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
451759 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
267800 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11006435 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8280810 usd
CY2022 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
28500000 usd
CY2022 us-gaap Payments For Repurchase Of Redeemable Convertible Preferred Stock
PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
28500000 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2781438 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6722654 usd
CY2023 IMNN Paymentoff Of Loan And Accrued Endofterm Fees
PaymentoffOfLoanAndAccruedEndoftermFees
6420000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3638562 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6722654 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11654275 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8093431 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17492841 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25586272 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5838566 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17492841 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
2500 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
2000 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
179542 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
4847359 usd
CY2023 IMNN Recognition Of Right Use Asset And Liability
RecognitionOfRightUseAssetAndLiability
1911049 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29327866 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19514977 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2781438 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
595 usd
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
34302 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
758418 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13387642 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
55795931 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
55795931 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35898234 usd
CY2022 IMNN Stock Issued During Period Value Issuance Of Preferred Stock Upon Financing
StockIssuedDuringPeriodValueIssuanceOfPreferredStockUponFinancing
28500000 usd
CY2022 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-28500000 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6722654 usd
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
13 usd
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
34468 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2673034 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29327866 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29327866 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zs1Te3mJdYQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zRwQr3E0IeR9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
248000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
197000 usd
CY2023 IMNN Number Of Shares Of Common Stock Issuable Upon Exercise Of Warrants And Equity Awards
NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards
1255642 shares
CY2022 IMNN Number Of Shares Of Common Stock Issuable Upon Exercise Of Warrants And Equity Awards
NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards
988389 shares
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19000000.0 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
15700000 usd
CY2023 IMNN Proceeds From Sale Of Net Operating Losses
ProceedsFromSaleOfNetOperatingLosses
1300000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9857087 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
21254485 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
9796291 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9857087 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
21227991 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
21254485 usd
CY2023Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Amortized Cost
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost
2467518 usd
CY2023Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Fair Value
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue
2490775 usd
CY2022Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Amortized Cost
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost
4005559 usd
CY2022Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Fair Value
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue
3994590 usd
CY2023Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Amortized Cost
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost
7328773 usd
CY2023Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Fair Value
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue
7366312 usd
CY2022Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Amortized Cost
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost
17222432 usd
CY2022Q4 IMNN Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Fair Value
DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue
17259895 usd
CY2023Q4 IMNN Available For Sale Debt Securities Amortized Cost Basis Current
AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent
9796291 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
9857087 usd
CY2022Q4 IMNN Available For Sale Debt Securities Amortized Cost Basis Current
AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent
21227991 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
21254485 usd
CY2023Q4 IMNN Available For Sale Securities Unrealized Gains Fair Value
AvailableForSaleSecuritiesUnrealizedGainsFairValue
9857087 usd
CY2023Q4 IMNN Available For Sale Securities Unrealized Holding Gains Less Than Twelve Months
AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths
60796 usd
CY2022Q4 IMNN Available For Sale Securities Unrealized Gains Fair Value
AvailableForSaleSecuritiesUnrealizedGainsFairValue
13278505 usd
CY2022Q4 IMNN Available For Sale Securities Unrealized Holding Gains Less Than Twelve Months
AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths
43508 usd
CY2022Q4 IMNN Available For Sale Securities Unrealized Loss Fair Value
AvailableForSaleSecuritiesUnrealizedLossFairValue
7975980 usd
CY2022Q4 IMNN Available For Sale Securities Unrealized Holding Losses Less Than Twelve Months
AvailableForSaleSecuritiesUnrealizedHoldingLossesLessThanTwelveMonths
-17014 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9857087 usd
CY2023Q4 IMNN Available For Sale Securities Unrealized Holding Gains Losses Less Than Twelve Months
AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths
60796 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
21254485 usd
CY2022Q4 IMNN Available For Sale Securities Unrealized Holding Gains Losses Less Than Twelve Months
AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths
26494 usd
CY2023 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
725824 usd
CY2022 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
502578 usd
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
431801 usd
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-49222 usd
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
431801 usd
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-49222 usd
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
1157625 usd
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
453356 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5838566 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11492841 usd
CY2022Q4 us-gaap Restricted Investments
RestrictedInvestments
6000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5838566 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17492841 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1481 shares
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2854178 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3192063 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2102272 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2643762 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
751906 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
548301 usd
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
1442659 usd
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
2196711 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1693383 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2139927 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
37583 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
234479 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
215402 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
20000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
205313 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3390521 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4794936 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1280385 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1567026 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1280385 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1567026 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.071 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.071 pure
CY2023 IMNN Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.031 pure
CY2022 IMNN Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.298 pure
CY2023 IMNN Effective Income Tax Rate Reconciliation Time Up
EffectiveIncomeTaxRateReconciliationTimeUp
-1.050 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.029 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.890 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.538 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.061 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.041 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
12.36
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67310000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
79800000 usd
CY2023Q4 IMNN Deferred Tax Assets Legal Act
DeferredTaxAssetsLegalAct
4929000 usd
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2016000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
13287000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
74255000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
93087000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
72974615 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
91519974 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1280385 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1567026 usd
CY2023 IMNN Net Operating Losses Expiration Description
NetOperatingLossesExpirationDescription
expire starting in 2029 through 2042
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.The Company’s income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years
CY2023 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged.
CY2023 us-gaap Stockholders Equity Note Changes In Capital Structure Retroactive Impact
StockholdersEquityNoteChangesInCapitalStructureRetroactiveImpact
To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company’s common stock fell below $1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period.
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86557736 shares
CY2023 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
5770516 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
300
CY2022Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
28500000 usd
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
300
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1000000 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
69650 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.92
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1381 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
12.04
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
100 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
9.45
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
69650 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.92
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
22100 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.92
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
59450 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.91
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
200 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.60
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
32100 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.23
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1063482 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
453766 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0339 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0481 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0174 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0397 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.000 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.136 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.000 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.139 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000 usd
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2021Q4 IMNN Earnout Milestone Liability
EarnoutMilestoneLiability
5396000 usd
CY2022 IMNN Gain Loss From Change In Fair Value Of Earn Out Milestone Liability
GainLossFromChangeInFairValueOfEarnOutMilestoneLiability
5396000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
175792 shares
CY2021Q4 IMNN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
20.96
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
7273 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
48.30
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
168519 shares
CY2022Q4 IMNN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
19.78
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
8459 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
37.29
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
160060 shares
CY2023Q4 IMNN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
18.86
CY2023 IMNN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y2M12D
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03 pure
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
142000 usd
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
117000 usd
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P24M
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
626323 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
543009 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
362976 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
370236 usd
CY2023Q4 IMNN Lessee Operating Lease Liability Payments Due Year Five After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAfterYearFour
30903 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1933447 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
308733 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1624714 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0998 pure
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
646633 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
644593 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
587744 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
601495 usd
CY2023 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
472000 usd
CY2022 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
535000 usd

Files In Submission

Name View Source Status
0001493152-24-011616-index-headers.html Edgar Link pending
0001493152-24-011616-index.html Edgar Link pending
0001493152-24-011616.txt Edgar Link pending
0001493152-24-011616-xbrl.zip Edgar Link pending
ex-97.htm Edgar Link pending
ex21-1.htm Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
imnn-20231231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
imnn-20231231_pre.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
imnn-20231231_cal.xml Edgar Link unprocessable
imnn-20231231_def.xml Edgar Link unprocessable
imnn-20231231_lab.xml Edgar Link unprocessable